Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 21, 2019
Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 11, 2016
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: September 29, 2016
Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 21, 2016
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.
Journal: Targeted oncology
Published: August 28, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: June 02, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Journal: The Lancet. Oncology
Published: February 24, 2015
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Journal: The New England journal of medicine
Published: January 20, 2012
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Journal: Cancer research
Published: December 30, 2011
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Journal: Cancer research
Published: December 20, 2011
Showing 1-10 of 10
Last Updated: 09/26/2026